



TCHF III

Founded in
2021

Located in
Belgium

Disease focus
Oncology

CEO
**Jean-Pierre
Latere**

Responsible partner
Michel Briejer

The company in a nutshell

- EsoBiotec is a **biotechnology** company focused on the development of innovative therapies to **fight cancer**.
- Jean-Pierre Latere, EsoBiotec's founder and CEO, is a **seasoned executive** with a strong track record in several international biotech and pharma companies.
- EsoBiotec is focused on a promising type of cancer treatment, known as **CAR-T cell therapy**, that uses a patient's own immune cells to recognize and destroy cancer.
- Current CAR-T cell therapies have yielded spectacular results in the treatment of cancer, but the complex production process is highly time-consuming and costly, limiting therapy access.
- The complexity of production is due to the fact that the patient's T-cells need to be harvested and processed outside the body, and then reinfused weeks later.
- EsoBiotec's mission is to transform CAR-T cell therapy into a **readily available, off-the-shelf product**, by using the patient's own body (*in vivo*) to produce the therapy.

Healthcare impact potential

EsoBiotec aims to begin its first clinical trials in 2026. In general, for a preclinical stage company, it will take around 10 years for the drug to be available to patients outside of trials.

The expected healthcare impact of the technology, once it reaches the market, is:



Major cost-savings due to a reduction in the need for costly manufacturing facilities, personnel, and transportation costs compared to current approaches. This is expected to decrease costs for the healthcare system, and to enable more patients to access this life-saving treatment.




Additional impact using the patient's own body will also lead to a more sustainable production and transportation process, resulting in lower use of energy and water, and a reduction in manufacturing waste.

If successful, EsoBiotec has the potential to be a disruptive game changer in the treatment of cancer, by making a currently complex and expensive but highly effective treatment available to more patients.

The problem that EsoBiotec is solving

Current CAR-T cell therapies require extensive handling of the patient's own immune cells outside the body (left figure). EsoBiotec's product could replace all these lengthy and expensive steps with a single injection by using the patient's own body as 'cell factory' (right figure – in grey steps not needed by EsoBiotec).



Current CAR-T cell therapy

Infrastructure required	Cell collection (apheresis) facilities, specialised transportation, dedicated manufacturing sites for patient-by-patient production
Time to treatment	3-5 weeks minimum required from decision to treat to actual treatment ¹
Total cost of care*	\$450 - 500k+ per treatment ²

EsoBiotec's in vivo CAR-T therapy

Infrastructure required	Production happens inside the patient's body, so no cell collection facilities, dedicated manufacturing sites or transportation required
Time to treatment	1-2 days from decision to treat to actual treatment
Total cost of care*	Expected to be much lower , as manufacturing has a much lower cost

* Direct & indirect costs (e.g. side effect management, administration); [1] American Society of Clinical Oncology Journal (2022); [2] American Journal of Managed Care (2021).

Approved CAR-T therapies

There are currently (end of 2023) 6 CAR-T products approved in US and EU.



Key facts on Kymriah

- The first CAR-T therapy, approved in 2017.
- In the main clinical trial **83%** of the patients experienced a complete response that **eliminated all signs of their cancer disease¹**.
- Emily Whitehead, the first patient treated, is over **10 years cancer free!¹**
- Reported list price in Europe of **300-320K EUR per patient**, with estimated additional costs for pre- and post-treatment of **50K EUR²**.

[1] National Cancer Institute; [2] Erasmus University CART health economics report.